"Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before."
www.medrxiv.org/content/10.1101/2021.06.01.21258176v2
52000 sample is fairly sizeable, and could be construed to support herd immunity theory. Either way, that's Good News I guess.
It's certainly a bigger population than the sample it took to determine that aspirins are no use against the virus.
www.recoverytrial.net/news/recovery-trial-finds-aspirin-does-not-improve-survival-for-patients-hospitalised-with-covid-19
The larger tests create something of a problem for smaller tests because they soak up the potential audience. I've read of a test which only requires 600 worldwide that is struggling, although that's also partly because the candidates have to be at a fairly specific state (iirc positive with mild to medium symptoms, and breathlessness, and not pregnant women and other groups - the safety rules are fairly restrictive)
And lastly, as it came by today, an article on "COVID-19 Can Lead to Diabetes" directorsblog.nih.gov/2021/06/08/how-covid-19-can-lead-to-diabetes/
|